Search
The findings of this postmarketing assessment of the safety of 2 new enhanced influenza vaccines support confidence in ongoing vaccine use
The P3-MumBubVax intervention is feasible and acceptable in the Australian public antenatal setting
Active vaccine safety surveillance leading to rapid detection of a safety signal would likely have resulted in earlier suspension of Fluvax from the vaccination programme
We found a numerically higher rate of preterm births among women who received 23vPPV in pregnancy compared to unvaccinated pregnant women
The review provides the basis for further research into the effects of acute and chronic UV radiation exposure on skin cells in the context of vaccination
Pathogenic SCN1A variants may be identified in infants with vaccine-proximate febrile seizures
Assessment of the persistence of bactericidal antibodies up to 4 years after a three-dose schedule of bivalent rLP2086
Existing evidence supporting the safety of vaccination during pregnancy should be used to reassure pregnant women and improve vaccine uptake in pregnancy
Immune responses after the initial vaccination persisted for the 12 months studied, with little additional response after the booster dose at 6 months
The Influenza Complications Alert Network (FluCAN) is a sentinel hospital-based surveillance programme operating in all states and territories in Australia